A phase I study of the fully human, fragment crystallizable-engineered, anti-CD-33 monoclonal antibody BI 836858 in patients with previously-treated acute myeloid leukemia

Sumithira Vasu,[1] Jessica K. Altman,[2] Geoffrey L. Uy,[3] Martin S. Tallman,[4] Ivana Gojo,[5] Gerard Lozanski,[6] Ute Burkard,[7] Annika Osswald,[7] Pamela James,[8] Björn Rüter[8] and William Blum[9]

[1]Division of Hematology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA; [2]Division of Hematology/Oncology, Northwestern University, Chicago, IL, USA; [3]Washington University School of Medicine, Siteman Cancer Center, St Louis, MO, USA; [4]Leukemia Service, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, NY, USA; [5]The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA; [6]Department of Pathology, The Ohio State University, Columbus, OH, USA; [7]Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach an der Riß, Germany; [8]Boehringer Ingelheim Pharmaceuticals, Inc, Ridgefield, CT, USA and [9]Department of Hematology and Medical Oncology, Emory University School of Medicine, Winship Cancer Institute, Atlanta, GA, USA

Correspondence:

WILLIAM BLUM - william.g.blum@emory.edu

doi:10.3324/haematol.2020.274118

Supplementary figures

Supplementary Figure 1: Comparison of individual and gMean of C_{max} (dose norm.) after single iv administration of 10 to 40 mg BI 836858 in Cycle 1 (1st and 2nd infusion)



Supplementary Figure 2: Correlation between Cmax of BI 836858 and CD33+ Blasts_ABS (in peripheral blood) after single iv administration of 10 to 40 mg BI 836858 in cycle 1 (1st and 2nd infusion)



Supplementary Figure 3. Proportion of NK cells over time in (A) peripheral blood and (B) bone marrow of patients with R/R AML treated with 40 mg BI 836858. R/R AML: relapsed or refractory acute myeloid leukemia; NK = natural killer; scr: screening; WBC: white blood cell